| Hepatitis B virus (HBV) | HBV vaccination [BII] | Hepatitis B negative |
| Hepatitis A virus (HAV) | HAV vaccination [BII] | Coinfected with HBV or hepatitis C virus, or high-risk exposures |
| Streptococcus pneumoniae | Pneumococcal vaccination (23-valent polysaccharide) | CD4+ cell count greater than 200 cells per mm3(200 × 109 per L) [BII] |
| CD4+ cell count less than 200 cells per mm3 [CIII] |
| Influenza | Inactivated vaccine | Annually |
| Pneumocystis jiroveci pneumonia | Trimethoprim/sulfamethoxazole (TMP-SMX; Bactrim, Septra) [AI] | CD4+ cell count less than 200 cells per mm3 [AI], or CD4+ cell count less than 14 percent or history of AIDS diagnosis [BII], or history of oral thrush [AII] |
| Toxoplasmosis | TMP-SMX [AII] | CD4+ cell count less than 100 cells per mm3 (100 × 109 per L) and toxoplasma IgG+ [AII] |
| Mycobacterium avium intracellulare complex | Azithromycin (Zithromax) [AI] or clarithromycin (Biaxin) [AI] | CD4+ cell count less than 50 cells per mm3 (50 × 109 per L) [AI] |
| Tuberculosis | Isoniazid (INH) [AII] | As per text. |